Immunotherapy following hematopoietic stem cell transplantation: Potential for synergistic effects

Myriam N. Bouchlaka, Doug Redelman, William J Murphy

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Hematopoietic stem cell transplantation (HSCT) is a particularly important treatment for hematologic malignancies. Unfortunately, following allogeneic HSCT, graft-versus-host disease, immunosuppression and susceptibility to opportunistic infections remain among the most substantial problems restricting the efficacy and use of this procedure, particularly for cancer. Adoptive immunotherapy and/or manipulation of the graft offer ways to attack residual cancer as well as other transplant-related complications. Recent exciting discoveries have demonstrated that HSCT could be expanded to solid tissue cancers with profound effects on the effectiveness of adoptive immunotherapy. This review will provide a background regarding HSCT, discuss the complications that make it such a complex treatment procedure following up with current immunotherapeutic strategies and discuss emerging approaches in applying immunotherapy in HSCT for cancer.

Original languageEnglish (US)
Pages (from-to)399-418
Number of pages20
JournalImmunotherapy
Volume2
Issue number3
DOIs
StatePublished - May 2010

Fingerprint

Hematopoietic Stem Cell Transplantation
Immunotherapy
Adoptive Immunotherapy
Transplants
Neoplasms
Disease Susceptibility
Opportunistic Infections
Residual Neoplasm
Graft vs Host Disease
Hematologic Neoplasms
Immunosuppression
Therapeutics

Keywords

  • Adoptive immunotherapy
  • Antigen-presenting cell
  • Graft-versus-host disease
  • Graft-versus-leukemia
  • Graft-versus-tumor
  • Hematopoietic stem cell transplantation
  • Myeloablative conditioning
  • Natural killer cell
  • Nonmyeloablative conditioning
  • Regulatory T cell

ASJC Scopus subject areas

  • Immunology and Allergy
  • Oncology
  • Immunology

Cite this

Immunotherapy following hematopoietic stem cell transplantation : Potential for synergistic effects. / Bouchlaka, Myriam N.; Redelman, Doug; Murphy, William J.

In: Immunotherapy, Vol. 2, No. 3, 05.2010, p. 399-418.

Research output: Contribution to journalArticle

@article{b408239461164a5fa12c67778dac07b8,
title = "Immunotherapy following hematopoietic stem cell transplantation: Potential for synergistic effects",
abstract = "Hematopoietic stem cell transplantation (HSCT) is a particularly important treatment for hematologic malignancies. Unfortunately, following allogeneic HSCT, graft-versus-host disease, immunosuppression and susceptibility to opportunistic infections remain among the most substantial problems restricting the efficacy and use of this procedure, particularly for cancer. Adoptive immunotherapy and/or manipulation of the graft offer ways to attack residual cancer as well as other transplant-related complications. Recent exciting discoveries have demonstrated that HSCT could be expanded to solid tissue cancers with profound effects on the effectiveness of adoptive immunotherapy. This review will provide a background regarding HSCT, discuss the complications that make it such a complex treatment procedure following up with current immunotherapeutic strategies and discuss emerging approaches in applying immunotherapy in HSCT for cancer.",
keywords = "Adoptive immunotherapy, Antigen-presenting cell, Graft-versus-host disease, Graft-versus-leukemia, Graft-versus-tumor, Hematopoietic stem cell transplantation, Myeloablative conditioning, Natural killer cell, Nonmyeloablative conditioning, Regulatory T cell",
author = "Bouchlaka, {Myriam N.} and Doug Redelman and Murphy, {William J}",
year = "2010",
month = "5",
doi = "10.2217/imt.10.20",
language = "English (US)",
volume = "2",
pages = "399--418",
journal = "Immunotherapy",
issn = "1750-743X",
publisher = "Future Medicine Ltd.",
number = "3",

}

TY - JOUR

T1 - Immunotherapy following hematopoietic stem cell transplantation

T2 - Potential for synergistic effects

AU - Bouchlaka, Myriam N.

AU - Redelman, Doug

AU - Murphy, William J

PY - 2010/5

Y1 - 2010/5

N2 - Hematopoietic stem cell transplantation (HSCT) is a particularly important treatment for hematologic malignancies. Unfortunately, following allogeneic HSCT, graft-versus-host disease, immunosuppression and susceptibility to opportunistic infections remain among the most substantial problems restricting the efficacy and use of this procedure, particularly for cancer. Adoptive immunotherapy and/or manipulation of the graft offer ways to attack residual cancer as well as other transplant-related complications. Recent exciting discoveries have demonstrated that HSCT could be expanded to solid tissue cancers with profound effects on the effectiveness of adoptive immunotherapy. This review will provide a background regarding HSCT, discuss the complications that make it such a complex treatment procedure following up with current immunotherapeutic strategies and discuss emerging approaches in applying immunotherapy in HSCT for cancer.

AB - Hematopoietic stem cell transplantation (HSCT) is a particularly important treatment for hematologic malignancies. Unfortunately, following allogeneic HSCT, graft-versus-host disease, immunosuppression and susceptibility to opportunistic infections remain among the most substantial problems restricting the efficacy and use of this procedure, particularly for cancer. Adoptive immunotherapy and/or manipulation of the graft offer ways to attack residual cancer as well as other transplant-related complications. Recent exciting discoveries have demonstrated that HSCT could be expanded to solid tissue cancers with profound effects on the effectiveness of adoptive immunotherapy. This review will provide a background regarding HSCT, discuss the complications that make it such a complex treatment procedure following up with current immunotherapeutic strategies and discuss emerging approaches in applying immunotherapy in HSCT for cancer.

KW - Adoptive immunotherapy

KW - Antigen-presenting cell

KW - Graft-versus-host disease

KW - Graft-versus-leukemia

KW - Graft-versus-tumor

KW - Hematopoietic stem cell transplantation

KW - Myeloablative conditioning

KW - Natural killer cell

KW - Nonmyeloablative conditioning

KW - Regulatory T cell

UR - http://www.scopus.com/inward/record.url?scp=77953435075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953435075&partnerID=8YFLogxK

U2 - 10.2217/imt.10.20

DO - 10.2217/imt.10.20

M3 - Article

C2 - 20635904

AN - SCOPUS:77953435075

VL - 2

SP - 399

EP - 418

JO - Immunotherapy

JF - Immunotherapy

SN - 1750-743X

IS - 3

ER -